US appeals court upholds Otsuka's patent for Abilify, with protection until 2015
This article was originally published in Scrip
Executive Summary
Otsuka has announced that a US appeals court ruling has upheld asserted claims of a key patent in litigation against several companies seeking FDA approval to market generic copies of Abilify (aripiprazole) – a ruling that is expected to help both Otsuka and partner Bristol-Myers Squibb ward off generic competition in the US until April 2015.